Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Classical hematology 1

Conditions

Neoplasm Metastasis 4Multiple Myeloma 4Carcinoma 4Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Unspecified Childhood Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Fibrosarcoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × reolysin × Clear all
NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Classical hematologyPlasma cell

Anemia, Multiple Myeloma

NCT03605719 2023-10-06

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Emory University

Phase 1 Completed
23 enrolled
Plasma cell

Multiple Myeloma

NCT02514382 2023-08-14

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

University of Southern California

Phase 1 Completed
14 enrolled
Plasma cell

Multiple Myeloma

NCT01533194 2015-04-15

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡